drugset

drugset / Trial / NCT02834611

Ceramide NanoLiposome in Patients With Advanced Solid Tumors

NCT02834611 ↗

Phase 1 Completed 14 enrolled Keystone Nano, Inc National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is a dose escalation study of Ceramide NanoLiposome in patients with advanced solid tumors.

Timeline

Start: 2017-03-15
Primary completion: 2023-08-03
Completion: 2023-11-01

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper The maximum tolerated dose was not reached and there were no dose-limiting toxicities. PMID 37736793 ↗

Publications

Ciner A, Gourdin T, Davidson J, Parette M, Walker SJ, Fox TE, Jiang Y. A phase I study of the ceramide nanoliposome in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2024 Jan;93(1):23-29. doi: 10.1007/s00280-023-04588-7. Epub 2023 Sep 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	C6 Ceramide	Unknown	—	Intravenous

Indications